ClinicalTrials.gg
TerminatedNCT01947946Updated Nov 24, 2015Results posted

Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma

A Phase 3 interventional study of Benralizumab and Placebo in Asthma, sponsored by AstraZeneca. Terminated at 48 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-11-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Why this study was terminated
Study terminated due to sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
37th of 39
13 · median 128
Started
2013
with 2 others
Phase 3
20 of 39
1 open now
Registered
9th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 37th largest by enrollment, is one of 3 that started in 2013, is one of 20 in phase 3, and was the 9th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on medium doses of ICS-LABA.

03

Conditions studied

  • Asthma

Keywords

  • Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures
  2. Female and male aged from 18 to 75 years, inclusively
  3. History of physician-diagnosed asthma requiring treatment with medium dose ICS (>250ug fluticasone dry powder formulation equivalents total daily dose) and a LABA, for at least 12 months prior to Visit 1
  4. Documented treatment with medium-dose ICS (>250ug and ≤500ug fluticasone dry powder formulation equivalents total daily dose) and LABA for at least 3 month prior to Visit 1

Exclusion criteria

Exclusion criteria:

  1. pulmonary disease other than asthma (e.g. active lung infection, , bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary aspergillosis/mycosis, Churg- Strauss syndrome, hypereosinophilic syndrome)
  2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could: - Affect the safety of the patient throughout the study - Influence the findings of the studies or their interpretations - Impede the patient's ability to complete the entire duration of study
  3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date is obtained or during the screening/run-in period 4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening/run-in period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Benra 30 mg q.4 Weeks

    Fixed 30 mg dose of benralizumab (every 4 weeks)

    Biological: Benralizumab

  • Experimental
    Benra 30 mg - Placebo q.8 Weeks

    Fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administered at the 4 week interim treatment visits to maintain blind).

    Biological: Benralizumab

  • Placebo comparator
    Placebo

    A (Dummy) injection

    Biological: Placebo

Interventions

  • BiologicalBenralizumab

    Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive. Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive.

  • BiologicalPlacebo

    Placebo subcutaneously on study week 0 until study week 44 inclusive.

06

What researchers measure

Primary outcomes

  1. Asthma Exacerbations Over 48 Weeks Treatment

    The number of asthma exacerbations over 48 weeks treatment will be counted

    Time frame: 48 weeks treatment

07

Results

Posted Nov 23, 2015

Participant flow

The study was stopped with 13 patients randomised

Participant flow — Overall Study
MilestoneBenra 30 mg q.4 WeeksBenra 30 Mg-Placebo q.8 WeeksPlacebo
Started355
Completed000
Not completed355

Outcome measures

PrimaryAsthma Exacerbations Over 48 Weeks Treatment

The number of asthma exacerbations over 48 weeks treatment will be counted

Time frame:
48 weeks treatment
Reported as:
Number · Number of events
Asthma Exacerbations Over 48 Weeks Treatment
Number of eventsBenra 30 mg q.4 WeeksBenra 30 Mg-Placebo q.8 WeeksPlacebo
Asthma Exacerbations Over 48 Weeks Treatment000

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benra 30 mg q.4 Weeks—0/3 (0%)0/3 (0%)
Benra 30 Mg-Placebo q.8 Weeks—0/5 (0%)0/5 (0%)
Placebo—0/5 (0%)1/5 (20%)
Most frequent other events
Most frequent other events
EventBenra 30 mg q.4 WeeksBenra 30 Mg-Placebo q.8 WeeksPlacebo
Prolonged expirationRespiratory, thoracic and mediastinal disorders0/30/51/5

Baseline characteristics

The number of participants for analysis will be from the full analysis set. The full analysis set consists of all patients randomized and receiving any investigational product, irrespective of their protocol adherence and continued participation in the study.

Age, Continuous
Age, Continuous(years)Benra 30 mg q.4 WeeksBenra 30 Mg-Placebo q.8 WeeksPlaceboTotal
Mean58.7 ± 15.7057.8 ± 6.3849.6 ± 6.3554.8 ± 9.32
Sex: Female, Male
Sex: Female, Male(Participants)Benra 30 mg q.4 WeeksBenra 30 Mg-Placebo q.8 WeeksPlaceboTotal
Female24511
Male1102
08

Study locations

48 sites
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    Glendale, Arizona, United States
  • Research Site
    San Jose, California, United States
  • Research Site
    Centennial, Colorado, United States
  • Research Site
    Miami, Florida, United States
  • Research Site
    Orlando, Florida, United States
  • Research Site
    Pembroke Pines, Florida, United States
  • Research Site
    Winter Park, Florida, United States
  • Research Site
    Lawrenceville, Georgia, United States
  • Research Site
    Savannah, Georgia, United States
  • Research Site
    Bellevue, Nebraska, United States
  • Research Site
    Las Vegas, Nevada, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Pittsburgh, Pennsylvania, United States
  • Research Site
    Warwick, Rhode Island, United States
  • Research Site
    Rock Hill, South Carolina, United States
  • Research Site
    Arlington, Texas, United States
  • Research Site
    Austin, Texas, United States
  • Research Site
    Dallas, Texas, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Sugarland, Texas, United States
  • Research Site
    Buenos Aires, Argentina
  • Research Site
    Ciudad de Buenos Aire, Argentina
  • Research Site
    São Paulo, Brazil
  • Research Site
    Ruse, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Varna, Bulgaria
  • Research Site
    Hamburg, Germany
  • Research Site
    Mainz, Germany
  • Research Site
    Bydgoszcz, Poland
  • Research Site
    Giżycko, Poland
  • Research Site
    Lubin, Poland
  • Research Site
    Ostrów Wielkopolski, Poland
  • Research Site
    Warszawa, Poland
  • Research Site
    Wrocław, Poland
  • Research Site
    Łódź, Poland
  • Research Site
    Żnin, Poland
  • Research Site
    Chelyabinsk, Russian Federation
  • Research Site
    Ekaterinburg, Russian Federation
  • Research Site
    Izhevsk, Russian Federation
  • Research Site
    Kazan, Russian Federation
  • Research Site
    Moscow, Russian Federation
  • Research Site
    Novosibirsk, Russian Federation
  • Research Site
    Pyatigorsk, Russian Federation
  • Research Site
    Saint Petersburg, Russian Federation
  • Research Site
    St. Petersburg, Russian Federation
  • Research Site
    Ulyanovsk, Russian Federation
  • Research Site
    Vladikavkaz, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2013
First posted
Sep 23, 2013
Start
Nov 2013
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results first posted
Nov 23, 2015
Last update
Nov 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01947946
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 23, 2013
Start date
Nov 2013
Primary completion
Jul 2014
Completion
Jul 2014
Results posted
Nov 23, 2015
Last update
Nov 24, 2015

Study contacts

William W. Busse, MD
principal investigator · Allergy, Pulmonary and Critical Care Medicine, Clinical Science Center 600 Highland Ave, Madison, WI USA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion